Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression

Abstract

Objective To evaluate the chemotherapy effect on diffuse large B-cell lymphoma(DLBCL) patients with different CD5 expression by 18F-FDG PET/CT, and discuss related influence factors. Methods We retrospectively analyzed the PET/CT manifestation of 55 patients initially diagnosed as DLBCL. Deauville 5-score(5-PS) standard was applied to compare the chemotherapy effect between DLBCL patients with CD5(+) and CD5(-), and analyze if there was difference in age, gender, Ann Arbor staging, B symptoms, invasion position, LDH, IPI or SUVmax in DLBCL patients with different CD5 expression. Results There was no significant difference in age, gender or SUVmax between CD5(+) and CD5(-) DLBCL patients (P=0.105, 0.931, 0.203); while there was significant difference in Ann Arbor staging, B symptoms, nodal or extranodal, LDH, IPI (P=0.005, 0.037, 0.014, 0.003, 0.029). The therapeutic effect on patients with CD5(-) was better than those with CD5(+) (P=0.018). Age, gender, SUVmax were not independent influence factors for chemotherapeutic effect (P=0.050, 0.230, 0.179), while Ann Arbor staging, B symptoms, nodal or extranodal, LDH and IPI were independent influence factors (P=0.007, 0.006, 0.043, 0.020, 0.015). Conclusion DLBCL patients with CD5(+) are prone to recurrence or new lesions in the follow-up period. There is no correlation between CD5 expression and gender or SUVmax. Ann Arbor staging, B symptoms, nodal or extranodal, LDH and IPI are independent influence factors for chemotherapeutic efficacy.

Keywords

• diffuse large b-cell lymphoma
• 18f-fdg pet/ct
• cd5
• ldh
• ipi
• chemotherapy effect